Cart
sales@molnova.com
Home - Products - Others - Other Targets - Dextromethorphan

Dextromethorphan

CAS No. 125-71-3

Dextromethorphan( Levomethorphan | RACEMETHORPHAN )

Catalog No. M26005 CAS No. 125-71-3

Dextromethorphan is an NMDA receptor antagonist used to treat cases of dry cough.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 131 In Stock
5MG 197 In Stock
10MG 298 In Stock
25MG 536 In Stock
50MG 764 In Stock
100MG 1053 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Dextromethorphan
  • Note
    Research use only, not for human use.
  • Brief Description
    Dextromethorphan is an NMDA receptor antagonist used to treat cases of dry cough.
  • Description
    Dextromethorphan is an NMDA receptor antagonist used to treat cases of dry cough.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Levomethorphan | RACEMETHORPHAN
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Antifection
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    125-71-3
  • Formula Weight
    271.404
  • Molecular Formula
    C18H25NO
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1ccc2CC3C4CCCCC4(CCN3C)c2c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Antiplasmodial and cytotoxic activity of coumarin derivatives from dried roots of Angelica gigas Nakai in vitro.Immunopharmacol Immunotoxicol. 2011 Dec;33(4):663-6.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Celgosivir

    Celgosivir (6 O-butanoyl castanospermine) is an inhibitor of α-glucosidase I. In vitro assay, it inhibits bovine viral diarrhoea virus (BVDV) ( IC50: 1.27 μM ).

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?

  • Zelminemab

    Zelminemab (AMG-301) is a human monoclonal antibody designed to target and inhibit the PACAP type I (PAC1) receptor .

Sign In Join Free